LB914 Dermatology evaluation of cutaneous immune related adverse event associated with higher checkpoint inhibitor retrial rates and improved survival

Abstract

Cutaneous immune related adverse events (cirAEs) are a common adverse effect of immune checkpoint inhibitors (ICI), at times severe enough to require discontinuation of ICI therapy. It is unclear whether the involvement of a board-certified dermatologist (BCD) in the care of cirAEs might affect ICI retrial or survival outcomes. As such, we sought to evaluate these potential associations. In this single institution cohort analysis of patients who developed a cirAE, we extracted demographic and clinical data from electronic medical records.